Welcome to our dedicated page for Monopar Therapeutics news (Ticker: MNPR), a resource for investors and traders seeking the latest updates and insights on Monopar Therapeutics stock.
Monopar Therapeutics Inc. develops clinical and preclinical biopharmaceutical programs for Wilson disease and oncology radiopharmaceuticals. News about MNPR centers on ALXN1840, also described as tiomolibdate choline, a late-stage investigational oral therapy for Wilson disease, including analyses from the Phase 3 FoCus trial, copper-balance data, neurology and hepatology conference presentations, and related peer-reviewed publications.
Company updates also cover the MNPR-101 radiopharmaceutical programs for uPAR-expressing cancers, including MNPR-101-Zr imaging activity, MNPR-101-Lu therapeutic development and IND clearance, and preclinical MNPR-101-Ac work. Recurring corporate themes include financial results, public offerings, balance-sheet updates, and commercial or executive infrastructure as the company advances its pipeline.
Monopar Therapeutics Inc. reported its first-quarter 2024 financial results and a strategic focus on its radiopharma pipeline. The company initiated the MNPR-101-Zr Phase 1 clinical trial and aims to launch the MNPR-101-RIT Phase 1 trial by Q4 2024 or Q1 2025. Monopar is winding down non-radiopharma programs to concentrate resources on radiopharma assets. The company is well-funded till at least June 30, 2025, with a net loss of $1.6 million for Q1 2024. R&D expenses decreased, while G&A expenses saw a slight drop.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.